Skip to main content
CHEMCLIN DIAGNOSTICS CO., LTD. logo

CHEMCLIN DIAGNOSTICS CO., LTD. — Investor Relations & Filings

Ticker · 688468 ISIN · CNE100005311 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2022-05-06 Investor Presentation
Country CN China
Listing Shanghai Stock Exchange 688468

About CHEMCLIN DIAGNOSTICS CO., LTD.

https://www.chemclin.com/

CHEMCLIN DIAGNOSTICS CO., LTD. specializes in the research, development, and manufacturing of in vitro diagnostic systems and reagents. The company is primarily recognized for its proprietary Light-initiated Chemiluminescent Assay (LiCA) technology, a homogeneous chemiluminescence platform that eliminates the need for washing steps, thereby enhancing testing efficiency and precision. Its product portfolio includes fully automated immunoassay analyzers and a comprehensive range of diagnostic kits covering infectious diseases, cardiac markers, thyroid function, tumor markers, and reproductive health. By integrating advanced biotechnology with automated instrumentation, the company provides clinical laboratories and medical institutions with high-sensitivity diagnostic solutions designed to improve patient care and laboratory workflow.

Recent filings

Filing Released Lang Actions
科美诊断技术股份有限公司关于召开2021年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about an upcoming investor presentation (业绩说明会) scheduled for May 16, 2022, to discuss the company's 2021 annual results. It mentions that the 2021 Annual Report has already been published on April 28, 2022, and this event is to provide further explanation and answer investor questions. The document does not contain actual financial statements or detailed financial data but rather details about the timing, format, and participation for the presentation. The document length is short (1442 characters), and it serves as a notice for the investor presentation event rather than the report itself. Therefore, it fits the category of Investor Presentation (IP).
2022-05-06 Chinese
科美诊断技术股份有限公司独立董事2021年度述职报告
Regulatory Filings
2022-04-27 Chinese
中信证券股份有限公司关于科美诊断技术股份有限公司使用闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution (中信证券股份有限公司) regarding the use of idle raised funds by 科美诊断技术股份有限公司 for cash management. It includes specifics about the raised funds, investment projects, cash management purposes, investment scope, risk control measures, and approval procedures. The document references regulatory guidelines and approvals but does not contain financial statements or comprehensive financial performance data. It is a regulatory compliance and verification report related to the use of raised funds, not a full annual or interim financial report. The document length is 4517 characters, which is relatively short but contains substantive content about the use of funds and regulatory compliance. This fits best under Audit Report / Information (AR), as it is a standalone audit/verification report on the use of funds and compliance with regulations, rather than an announcement or a full financial report. FY 2021
2022-04-27 Chinese
科美诊断技术股份有限公司独立董事关于第一届董事会第十八次会议相关事项的独立意见
Regulatory Filings
2022-04-27 Chinese
科美诊断技术股份有限公司2022年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2022年第一季度报告' which translates to '2022 First Quarter Report'. It contains detailed financial data including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2022. The report explicitly states it is unaudited and covers a period shorter than a full fiscal year (quarterly). The presence of comprehensive financial statements and analysis for a quarter period clearly identifies this as an Interim / Quarterly Report. The document length is about 15,000 characters, indicating it is the full report, not just an announcement or summary. Therefore, the correct classification is 'IR' (Interim / Quarterly Report). Q1 2022
2022-04-27 Chinese
科美诊断技术股份有限公司2021年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the 2021 annual report summary of 科美诊断技术股份有限公司, containing detailed company information, business overview, industry analysis, financial data for multiple years including 2021, 2020, and 2019, and quarterly financial data for 2021. It includes management discussion and analysis, risk factors, shareholder information, and dividend distribution plans. The length is substantial (11,976 characters), and it contains actual financial statements and substantive financial data. The document is not a brief announcement or a certification letter but a comprehensive report summarizing the company's yearly performance and outlook. Therefore, it fits the definition of an Annual Report (10-K). FY 2021
2022-04-27 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.